Think Brain Tumor
Minimally invasive, more effective treatments
When it comes to restoring quality of life, experience matters. Our surgeons have helped lead the way world-wide in advancing safe and effective keyhole and endoscopic brain tumor removal. ”Minimally invasive” is here today, every day at PNI. Ask our patients.
Clinical Trials & Novel Approaches
Our neuro-oncologists are at the forefront of applying brain tumor genomics to developing personalized treatments, including the evaluation of clinical trial eligibility. We provide targeted therapies and advanced treatment options patients may not have elsewhere.
Conditions We Treat:
There’s Always Time For a Second Opinion
If you or someone you care for have been recently diagnosed with a brain or skull base tumor (benign or malignant) there’s time for you to get another viewpoint. We’ll provide a rapid review of your medical records and imaging and give you our unique perspective on the optimal treatment pathway.
Get a Second Opinion
If you live in the United States outside Greater Los Angeles or are living abroad, our physicians can promptly review your imaging studies and other tests, and provide a recommendation on treatment options.Get a Second Opinion
Pacific Brain Tumor Center News, Healthy Living and Education
Pacific Neuroscience Institute Physicians Named “L.A.’s Top Doctors” of 2021
This year, seven of Pacific Neuroscience Institute’s physicians were included in Los Angeles Magazine’s April 2021 roster of “L.A.’s Top Doctors.” The results were based on a Los Angeles Magazine survey that asked physicians throughout Los Angeles County to identify the doctors they considered to be at the…
PNI’s 2020 Year-in-Review & What To Expect in 2021
PNI’s Year-in-Review 2020 was, despite the pandemic, a strong year for clinical care delivered by PNI providers with multiple milestones being achieved. We’ve entered 2021 with a deep commitment to treating our patients at our ten centers of excellence, doing groundbreaking research, providing innovative clinical…
ONCOLOGY Clinical Trials Round-Up: March 2021
New Studies EpicentRx Beta-Prime: A Phase I, First in Human, Study to Evaluate the Safety and Tolerability of AdAPT-001 in Subjects with Refractory Solid Tumors (NCT04673942) Actively Recruiting Studies Brain Cancer (Primary) – Glioma Aadi Bioscience (PDF): A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade…